D3.122 - Real-World Outcomes Of Tezepelumab In Severe Asthma After 12 Months Of Treatment

Tezepelumab targets thymic stromal lymphopoietin (TSLP), an epithelial-derived cytokine implicated in asthma pathogenesis. We evaluated 12-month real-world safety and effectiveness outcomes in a tertiary hospital cohort in Madrid.

Retrospective, descriptive, observational study including patients treated withTezepelumab for ≥12 months in a Multidisciplinary Severe Asthma Unit. Collectedvariables included clinical characteristics, biomarkers, exacerbations, systemic glucocorticoid (GC) use, asthma control, adverse events, and therapeutic failure.

Eighteen patients completed 12 months of Tezepelumab (210 mg every 4 weeks). The cohort was 66.7% female; mean BMI was 29.67±4.84 kg/m²; 27.8% were biologic-naïve and 16.7% had nasal polyposis. After initiation, 72.2% required no systemic GC courses, while 27.8% required ≥1 course (GC=1: 5.6%; GC=2: 11.1%; GC=4: 11.1%). Among five baseline steroid-dependent patients, two (40%) achieved complete systemic corticosteroid withdrawal at 12 months. Exacerbations decreased significantly, and 66.7% had no exacerbations after starting Tezepelumab. Hospital admissions declined numerically without statistical significance. Asthma control improved, with a significant increase in the Asthma Control Test (ACT); FeNO decreased significantly; and FEV1 increased significantly. Total IgE decreased significantly, while blood eosinophilcounts decreased without statistical significance.

In routine clinical practice, Tezepelumab showed an excellent safety profile and a low rate of therapeutic failure at 12 months. Treatment was associated with improved asthma control and lung function, fewer exacerbations, and reduced airway inflammation and total IgE. Most patients required no systemic GC courses, and 40% of baseline steroid-dependent patients achieved complete withdrawal.